Adipotide Research: Mechanism, Primate Data & Kidney Findings
Adipotide (FTPP, proapoptotic peptide) has a robust foundation of peer-reviewed animal trials, in-vitro tissue assays and non-human primate data. This page covers how it works, what the studies actually showed, and the kidney findings that stopped its development as a weight-loss drug.
Kidney toxicity documented
Human and primate trials recorded dose-dependent, reversible kidney lesions and dehydration. Read the research before handling.
Mechanism of action
Developed by researchers at the MD Anderson Cancer Center, Adipotide is a synthetic, dual-domain peptidomimetic. Rather than altering brain chemistry to suppress appetite like classic diet drugs, it seeks out the specific blood vessels feeding white fat tissue, binds to them, and destroys them — a "starve-the-fat" mechanism.
The homing domain (CKGGRAKDC) acts like a homing missile. It targets and locks onto two proteins — prohibitin and ANXA2 — that are uniquely expressed on the surface of blood vessels feeding white adipose (fat) tissue.
The destruction domain (D(KLAKLAK)2) takes over once the peptide is attached. It enters the vascular cell and disrupts the mitochondrial membrane, triggering apoptosis (cellular suicide) in the fat tissue's blood supply. Without that blood supply, the fat tissue is reabsorbed.
The studies
The published Adipotide literature spans in-vitro tissue assays, rodent metabolic models and a landmark non-human primate trial. Each study below sets out the delivery method used, the hypothesis being tested and what the data actually reported.
Target-specific vascular destruction (in-vitro assays)
Testing whether the peptide can tell the difference between blood vessels feeding fat tissue and those feeding vital organs — i.e. whether it destroys fat vasculature without causing system-wide vascular damage.
In-vitro cell culture and tissue assays · isolated endothelial cells from fat tissue and from other organ systems exposed to Adipotide
- Selectively killed
- Fat-tissue endothelial cells
- Spared
- Non-fat tissue vessels
- Prohibitin
- Target identified
valid targetable marker
Benefits shown in the data
- Adipotide killed fat-tissue endothelial cells highly selectively while completely sparing non-fat tissue vessels.
- This confirmed prohibitin works as a valid "zip code" the peptide can use for selective fat reduction rather than indiscriminate vascular damage.
- The selectivity seen here is the whole basis of the compound — without it, the destruction domain would damage vasculature everywhere.
- In-vitro selectivity does not automatically translate to whole-organism selectivity; the primate and human work later showed low-level prohibitin expression in the kidney matters.
Rapid weight loss and belly fat reduction (primate model)
Testing whether starving fat tissue of blood and oxygen forces the body to rapidly reabsorb and eliminate deep abdominal white fat in a species physiologically close to humans.
Obese rhesus monkeys · daily subcutaneous (sub-Q) injections · 28-day treatment period
- 11%
- Total body weight reduction
- 27%
- Visceral (belly) fat drop
- None observed
- Food aversion / nausea
average, in 4 weeks
measured by MRI
Benefits shown in the data
- Subjects lost an average of 11% of total body weight in just four weeks — an unprecedented rate for the model.
- MRI scans showed a 27% drop in visceral fat, the deep abdominal fat most strongly linked to metabolic disease.
- Unlike appetite-suppressing drugs, the monkeys showed no food aversion and no standard nausea, indicating the effect was not driven by making the animals feel unwell.
- The weight loss came from destroying the fat tissue's blood supply, not from reducing food intake — a genuinely different mechanism to incretin drugs.
- The same study is where dose-dependent kidney findings were first documented in primates (see the research context section below).
Reversal of type 2 insulin resistance (rodent metabolic model)
Testing whether rapidly removing inflammatory white fat tissue takes the burden off the pancreas and resets natural insulin sensitivity.
Genetically obese, diabetic rodent models · subcutaneous injection with metabolic tracking
- Normalised
- Glucose tolerance
- Reversed
- Insulin resistance
- Fat loss
- Driver
not direct pancreatic action
Benefits shown in the data
- Adipotide treatment completely normalised glucose tolerance and reversed insulin resistance in the diabetic models.
- The effect came from eliminating fat cells that release pro-inflammatory cytokines, allowing the liver and muscle to process blood sugar efficiently again.
- The metabolic improvement is downstream of fat loss — it is a consequence of removing inflammatory adipose tissue rather than a separate insulin pathway effect.
- These are rodent data; no controlled human trial has reproduced the glycaemic result.
Storage & handling
Adipotide is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water added slowly down the inner wall of the vial; swirl gently until fully dissolved and never shake.
Store reconstituted solution at 2-8 °C, protect from light, and use within your lab's defined stability window. Avoid repeated freeze-thaw cycles.
The clinical catch: human trial and kidney findings
Because the primate data was so exceptional, a human clinical trial was started in obese patients with prostate cancer. That is where the compound ran into real safety hurdles — and they are physiological, not paperwork, so they are worth understanding properly.
Kidney toxicity (nephrotoxicity)
In both the monkey trials and the early human evaluations, high doses of Adipotide caused reversible kidney lesions and mild-to-moderate renal impairment. The reason is mechanical rather than mysterious: the kidneys also express low levels of prohibitin, so the homing domain accidentally binds to some cells in the renal tubules and the destruction domain does its job there too. The damage reported was dose-dependent and reversed after dosing stopped.
Dehydration and electrolyte imbalance
The cell changes in the kidney left the tubules temporarily unable to concentrate urine properly, which produced notable dehydration and electrolyte-balance risk during treatment.
Development halted as a weight-loss drug
Because of these localised kidney concerns, mainstream pharmaceutical backing for Adipotide as a casual weight-loss compound was stopped. Importantly, the fat-loss data itself was never in doubt — the issue was the therapeutic window between the dose that shrinks fat and the dose that stresses the kidney.
Still actively studied in oncology
Adipotide remains classified strictly as an unapproved research chemical, and it continues to be studied in niche oncology frameworks where the goal is to starve tumours that depend on a fat-heavy microenvironment — a setting where a narrower safety margin is more acceptable.
Research use only
Adipotide is not an approved therapy anywhere for weight loss or any other indication. Material supplied here is strictly for laboratory research and is not for human or veterinary use.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.